AIM ImmunoTech Inc. (LON:0A4Y)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 4.76M +7.7% |
| Revenue (ttm) | 71.19K -35.6% |
| Net Income | -10.05M |
| EPS | -5.06 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,347 |
| Open | 0.4822 |
| Previous Close | 0.4369 |
| Day's Range | 0.4240 - 0.4822 |
| 52-Week Range | 0.2226 - 34.1360 |
| Beta | 1.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also ... [Read more]
Financial Performance
In 2025, AIM ImmunoTech's revenue was $88,000, a decrease of -48.24% compared to the previous year's $170,000. Losses were -$13.96 million, -19.41% less than in 2024.
Financial numbers in USD Financial StatementsNews
Infosys Collaborates with CMMI Institute to Shape Enterprise AI Maturity Framework; Achieves Milestone Recognition
As a pilot participant, Infosys contributed to shaping the CMMI AI Maturity (AIM) framework – bringing enterprise-scale AI practices, governance models, and real-world deployment insights – powered by...
AIM ImmunoTech Inc trading resumes
09:50 EDT AIM ImmunoTech (AIM) Inc trading resumes
AIM ImmunoTech announces $2.65M registered direct offering
AIM ImmunoTech (AIM) announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross...
AIM ImmunoTech Inc trading halted, news pending
09:27 EDT AIM ImmunoTech (AIM) Inc trading halted, news pending
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”), today announced that it has entered into definitive agreements for a registered direc...
AIM ImmunoTech registers to sell 31.29M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 31.29M shares of common stock. The company is not selling any…
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Company remains on track for a planned December 2026 evaluation of the clinical trial's primary endpoint Company remains on track for a planned December 2026 evaluation of the clinical trial's primary...
AIM ImmunoTech Registration statement: Registration filing
AIM ImmunoTech filed a registration statement on June 8, 2026, providing details about a securities offering with the SEC.
AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness
Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen's previously published antiviral research
3 Penny Stocks Drawing Market Attention, 6/2/26
Hitek Global ($HKIT), Sphere 3D ($ANY), and AIM ImmunoTech ($AIM) are the three penny stocks to watch on June 2, according to TipRanks’ Penny Stock Screener tool. Penny stocks are…
AIM ImmunoTech enrolls final subject in pancreatic cancer development program
AIM ImmunoTech (AIM) announced enrollment of the final subject in its pancreatic cancer development program, barring disqualifying pre-treatment circumstances. The final planned subject is scheduled f...
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Trea...
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola
AIM ImmunoTech Inc trading resumes
15:20 EDT AIM ImmunoTech (AIM) Inc trading resumes
AIM ImmunoTech announces $2.4M registered direct offering
AIM ImmunoTech (AIM) announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7.52M shares of common stock…
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct ...
AIM ImmunoTech Inc trading halted, news pending
14:57 EDT AIM ImmunoTech (AIM) Inc trading halted, news pending
CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework
SCHAUMBURG, Ill.--(BUSINESS WIRE)-- #isaca--CMMI Institute, a global leader in helping organizations reduce risk, boost performance, and build capability, is now extending this guidance to artificial ...
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
Increase in stockholder equity and note extension strengthen Company's ability to advance pancreatic cancer development strategy Increase in stockholder equity and note extension strengthen Company's ...
AIM ImmunoTech Quarterly report: Q1 2026
AIM ImmunoTech has published its Q1 2026 quarterly earnings report on May 15, 2026.
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon...
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drug...
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin Final UPMC Primary Endpoint Report Details Positive Data fro...
AIM ImmunoTech Transcript: Virtual Investor Closing Bell
Ampligen’s focus on late-stage pancreatic cancer is driven by strong clinical data, significant unmet need, and robust market opportunity. The ongoing phase II DURIPANC study shows positive interim results, with phase III planning underway in partnership with Thermo Fisher Scientific. Orphan drug status and patent protection support long-term value and potential for major partnerships.
AIM ImmunoTech highlights accelerating momentum in pancreatic cancer program
AIM ImmunoTech (AIM) highlighted accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, Phase 2 clinical signals, and a strengthening global regulatory...